Publications by authors named "Ofer Rotem"

Claim this Profile
A
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter Study.
Itamar Averbuch, Sarit Appel, Philip Blumenfeld, Alina Goltser, Oded Icht, Ofer Rotem

Int J Radiat Oncol Biol Phys· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes.
Belal Krayim, Walid Shalata, Jair Bar, Mor Moskovitz, Ofer Rotem

Lung Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of brain MRI screening on stage IV NSCLC patients: A real world look at guidelines based care.
Efraim Waizman, Elizabeth Dudnik, Inbar Lavie, Ofer Rotem, Alexandra Amiel

J Neurol Sci· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.
Raz Mutai, Iryna Kuchuk, Alexandra Goldshtein, Rinat Yerushalmi, Ofer Rotem

Breast Cancer Res Treat· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seeing the Trees From the Forest: Challenges in Subgroup Analysis-Based Guidelines in Oncology.
Ofer Rotem, Karyn Revital Geiger, Ekaterina Hanovich, Mor Moskovitz, Noga Kurman

Oncol Rev· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment.
Itamar Averbuch, Roi Tschernichovsky, Shlomit Yust-Katz, Ofer Rotem, Dror Limon

J Neurooncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
Nir Peled, Laila C Roisman, Esther Levison, Julia Dudnik, Elena Chernomordikov, Ofer Rotem

Int J Radiat Oncol Biol Phys· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literature.
Itamar Averbuch, Roi Tschernichovsky, Oded Icht, Daniel A Goldstein, Raz Mutai, Ofer Rotem

Thorac Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study.
Ofer Rotem, Idit Peretz, Michelle Leviov, Iryna Kuchuk, Amit Itay, Rotem Merose

NPJ Breast Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy.
Ofer Rotem, Alona Zer, Lilach Yosef, Einat Beery, Hadar Goldvaser

Biomedicines· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course.
Roi Tschernichovsky, Itamar Averbuch, Daniel Alex Goldstein, Raz Mutai, Elizabeth Dudnik, Ofer Rotem

Transl Lung Cancer Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).
Jair Bar, Nir Peled, Shiruyeh Schokrpur, Mirjana Wolner, Ofer Rotem

J Thorac Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience with capmatinib in exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Ofer Rotem

Ther Adv Med Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.
Nir Peled, Waleed Kian, Edna Inbar, Iris M Goldstein, Melanie Zemel, Ofer Rotem

Neurooncol Adv· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer.
Orly Yariv, Raz Mutai, Ofer Rotem, Daliah Tsoref, Yasmin Korzets

Oncology· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer.
Yosef Landman, Oded Jacobi, Noga Kurman, Orly Yariv, Idit Peretz, Ofer Rotem

Oncoimmunology· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
Oded Jacobi, Yosef Landman, Daniel Reinhorn, Oded Icht, Michal Sternschuss, Ofer Rotem

Oncology· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
Daniel Reinhorn, Iryna Kuchuk, Tzippy Shochat, Bella Nisenbaum, Aaron Sulkes, Ofer Rotem

Breast Cancer Res Treat· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Oded Icht, Naama Darzi, Shai Shimony, Oded Jacobi, Daniel Reinhorn, Ofer Rotem

J Thromb Haemost· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence.
Elizabeth Dudnik, Mor Moskovitz, Abed Agbarya, Teodor Gottfried, Tzippy Shochat, Ofer Rotem

Int J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors.
Elizabeth Dudnik, Jair Bar, Assaf Moore, Teodor Gottfried, Mor Moskovitz, Ofer Rotem

Front Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.
Elizabeth Dudnik, Samuel Kareff, Mor Moskovitz, Chul Kim, Stephen V Liu, Ofer Rotem

J Immunother Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome.
Matan Ben-Zion Berliner, Rinat Yerushalmi, Inbar Lavie, Alexandra Benouaich-Amiel, Daliah Tsoref, Ofer Rotem

Breast Cancer Res Treat· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Ofer Rotem

Oncoimmunology· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC.
Omer Gal, Elizabeth Dudnik, Ofer Rotem, Inbar Finkel, Idit Peretz

J Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis